The Department of Justice (DOJ) and the Drug Enforcement Agency (DEA) have officially reclassified certain medical cannabis products, moving them from Schedule I to Schedule III under the Controlled Substances Act. This federal medical cannabis reclassification specifically applies to products approved by the Food and Drug Administration (FDA).
The policy adjustment follows an executive order issued by President Donald Trump in December of the previous year, which aimed to accelerate the reclassification process. While completed during the Trump administration, the initiative to reclassify medical cannabis was initially directed by former President Joe Biden in late 2022, according to a breakdown from The Ohio State University.
Federal Reclassification Details
The shift to Schedule III places FDA-approved medical cannabis products alongside substances such as ketamine and Tylenol with codeine. The DEA defines Schedule III drugs as having “a moderate to low potential for physical and psychological dependence.” This reclassification does not extend to recreational cannabis, which remains an illegal substance under Schedule I, alongside drugs like cocaine and heroin.
Jervonne Singletary, compliance and government relations officer for Parallel, the parent company of Texas medical cannabis provider goodblend, noted the significance of the change, stating, “It legitimizes us federally.” Singletary added, “We’ve been operating under agreements and gentleman’s handshakes for over 10 years now,” as reported by Spectrum Local News.
Financial and Operational Implications
The reclassification carries substantial financial implications for state-licensed medical cannabis operators. A primary impact is the exemption from Internal Revenue Service (IRS) Code section 280E.
IRS Code Section 280E Exemption
Historically, IRS Code section 280E has prevented state-legal medical cannabis operations from deducting standard business expenses, including rent and payroll, due to cannabis’s Schedule I status. With the move to Schedule III, operators are now exempt from this code. Singletary indicated that this change would allow companies to realize cost savings.
Banking and Transactional Changes
Another area potentially affected is consumer transactions. The previous Schedule I status of cannabis products often precluded the use of credit cards for purchases. With the new Schedule III classification, there is a possibility that customers may soon be able to use credit cards for medical cannabis products. However, Katharine Harris, a drug policy fellow at Rice University, cautioned that credit card companies and banks are risk-averse entities and may still choose not to facilitate these transactions. Harris also noted that some stakeholders are advocating for separate legislation to specifically address banking issues within the cannabis industry.
Texas Compassionate Use Program Context
The Texas Compassionate Use Program (TCUP), which has been operational since 2015, is among the 40 states and Washington, D.C., that have established medical cannabis programs. Nicholas Fallon, market president for goodblend, stated that while the reclassification would not alter the operational procedures at state growing sites, which are already subject to strict regulations by the Department of Public Safety (DPS) to ensure plant accountability, the financial aspects of cultivation would change.
Looking ahead, Harris mentioned a hearing scheduled for June 29 to reconsider the classification of recreational cannabis products, indicating ongoing policy discussions within the broader cannabis sector.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
